Retatrutide: The Triple Agonist That Could Outperform Tirzepatide

Retatrutide (LY3437943) is Eli Lilly's investigational triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. In Phase 3 trials, participants lost up to 28.7% of body weight at 68 weeks, the highest figure recorded in any obesity drug trial and results that rival bariatric surgery outcomes. The addition of glucagon receptor agonism increases energy expenditure and promotes liver fat oxidation, which differentiates retatrutide from dual agonists like tirzepatide. FDA approval is expected in late 2027, with NDA submission projected for Q4 2026.

This article examines what makes triple agonism mechanistically different from dual agonism, reviews the Phase 3 TRIUMPH program data, compares efficacy against tirzepatide, and provides a realistic timeline for FDA approval.

What Is Retatrutide and How Does It Work?

Retatrutide is a single 39-amino-acid peptide engineered from a GIP backbone to activate three distinct hormone receptors: GLP-1R, GIPR, and GCGR (the glucagon receptor). A fatty diacid moiety extends its half-life to approximately six days, allowing once-weekly subcutaneous injection.

The three receptor targets each contribute different metabolic effects:

GLP-1 Receptor (GLP-1R): Activation enhances glucose-stimulated insulin secretion, slows gastric emptying, and promotes satiety. This receptor is the primary target of semaglutide (Ozempic/Wegovy) and one of two targets for tirzepatide (Mounjaro/Zepbound).

GIP Receptor (GIPR): GIP facilitates insulin secretion in a glucose-dependent manner and influences lipid metabolism. Retatrutide is more potent at GIPR than at either of its other two targets (EC50: 0.0643 nM), which may enhance fat reduction beyond what GLP-1 agonism alone can achieve.

Glucagon Receptor (GCGR): This is retatrutide's differentiating feature. Glucagon receptor activation promotes hepatic fatty acid oxidation, increases thermogenesis, stimulates lipolysis in adipose tissue, and raises resting energy expenditure. The glucagon component essentially forces the body to burn additional fuel at the cellular level.

The combination addresses a core limitation of prior anti-obesity drugs: when you lose weight, your metabolism slows down (adaptive thermogenesis). Glucagon agonism counteracts this slowing by increasing energy expenditure, which may explain why retatrutide produces greater weight loss than compounds relying solely on appetite suppression.

How Much Weight Loss Does Retatrutide Produce?

The TRIUMPH-4 trial, reported in December 2025, delivered the highest weight loss figures ever recorded in a Phase 3 obesity trial:

The 28.7% weight reduction at the 12 mg dose approaches outcomes seen with bariatric surgery, which typically produces 25-35% weight loss depending on procedure type.

Phase 2 data published in the New England Journal of Medicine showed a dose-dependent response: 24.2% weight loss at 12 mg over 48 weeks. The longer TRIUMPH-4 trial extended these results, suggesting durability beyond one year of treatment.

Citi analysts project that TRIUMPH-1, which runs for 80 weeks, could show weight loss exceeding 30% at its primary endpoint.

How Does This Compare to Tirzepatide?

A network meta-analysis comparing retatrutide and tirzepatide found retatrutide produced greater absolute weight reduction:

• Retatrutide: Mean difference of -16.34 kg (95% CI: -22.11 to -10.56)
• Tirzepatide: Mean difference of -11.82 kg (95% CI: -15.08 to -8.56)

Tirzepatide's Phase 3 SURMOUNT-1 trial showed approximately 21% weight loss at 72 weeks, compared to retatrutide's 28.7% at 68 weeks. A head-to-head clinical trial directly comparing the two drugs is underway, with results expected in December 2026.

The weight loss advantage likely stems from the glucagon component. In preclinical studies, retatrutide reduced food intake and increased energy expenditure compared to calorie-matched controls, an effect attributable to glucagon receptor agonism.

What Does Retatrutide Do for Liver Fat?

The Phase 2a MASLD trial produced some of the most striking data in retatrutide's development program. At 48 weeks, liver fat reduction by dose:

The 86% reduction in liver fat at the highest dose exceeds results from semaglutide (which achieved 62.9% MASH resolution in Phase 3 ESSENCE) and tirzepatide (73.3% MASH resolution in Phase 2 SYNERGY-NASH).

Glucagon receptor activation directly increases hepatic fatty acid oxidation, meaning the liver burns its own stored fat. By 24 weeks, participants on retatrutide 4 mg and above showed significant metabolic improvements: triglycerides dropped 35-40%, leptin decreased 29-56%, and beta-hydroxybutyrate (a marker of fat burning) increased 78-181%.

Eli Lilly has included MASLD as a target indication in its Phase 3 program, with a dedicated liver disease trial (NCT06859268) using biopsy endpoints to evaluate whether retatrutide can resolve steatohepatitis and fibrosis.

What Are the Side Effects?

Retatrutide's adverse event profile is similar to other incretin-based therapies, with gastrointestinal symptoms being most common. From TRIUMPH-4 at 68 weeks:

The dysesthesia finding is a new safety signal that emerged in Phase 3 but was not prominent in earlier Phase 2 data. Dysesthesia refers to altered touch sensations (tingling, burning, prickling, or numbness) that patients described as unusual but not painful.

At 12 mg, roughly 1 in 5 patients experienced dysesthesia. Lilly reported these events were generally mild, self-limiting, and rarely led to treatment discontinuation. The glucagon receptor component is suspected as the contributing factor, since this side effect is not seen at comparable rates with semaglutide or tirzepatide.

The network meta-analysis found that adverse events were more frequent with retatrutide (RR 4.10, 95% CI: 1.42-11.84) compared to tirzepatide (RR 2.78, 95% CI: 1.98-3.91). Eli Lilly has stated that dysesthesia will be monitored across all ongoing TRIUMPH trials.

Cardiovascular risk markers improved on retatrutide: non-HDL cholesterol, C-reactive protein, and triglycerides all decreased significantly. Systolic blood pressure dropped by 14.0 mmHg at the 12 mg dose.

What Is the TRIUMPH Phase 3 Program?

Eli Lilly is running eight Phase 3 trials under the TRIUMPH banner, enrolling more than 5,800 participants across multiple indications:

Obesity/Weight Management:

• TRIUMPH-1: Pivotal 80-week obesity trial forming the basis of FDA approval
• TRIUMPH-2: Obesity with type 2 diabetes, including a subset with obstructive sleep apnea
• TRIUMPH-3: Obesity with established cardiovascular disease (BMI ≥35)
• TRIUMPH-4: Obesity with knee osteoarthritis (completed, reported December 2025)
• TRIUMPH-9: Obesity without type 2 diabetes

Cardiovascular Outcomes:

• TRIUMPH-Outcomes: 10,000-patient trial evaluating whether retatrutide reduces major adverse cardiovascular events (MACE). Results expected 2028-2029.

Related Programs:

• TRANSCEND-T2D: Includes head-to-head comparison of retatrutide vs. semaglutide in adults with type 2 diabetes. The TRANSCEND-T2D-1 trial reported in March 2026 showed A1C reductions of up to 2.0% and weight loss of 16.8% (36.6 lbs) at 40 weeks.
• SYNERGY: Dedicated MASLD/MASH program with 4,500-participant outcomes trial using liver biopsy endpoints.

The remaining TRIUMPH trials are expected to report throughout 2026, with the full data package supporting NDA submission.

When Will Retatrutide Be FDA Approved?

Retatrutide is not yet FDA approved. Here is the projected timeline based on current trial completion estimates:

Q4 2026: TRIUMPH trials complete primary endpoint data collection. Eli Lilly compiles data package.

Late 2026 / Early 2027: New Drug Application (NDA) submitted to FDA.

Late 2027: FDA decision under standard 10-12 month review timeline. A priority review designation could accelerate this to mid-2027.

Q1-Q2 2028: Commercial launch (most likely scenario).

Polymarket, where bettors wager real money on outcomes, gives only 18% odds of FDA approval in 2026, with 2027 being the consensus expectation. GlobalData projects 2027 approval with 2031 sales forecasted at $15.6 billion.

Best case: Phase 3 completion by late 2026, NDA submission in Q1 2027, priority review approval by October 2027. Worst case: Safety signals or inconsistent data push approval into 2028 or beyond.

How Is Retatrutide Different from Tirzepatide?

The fundamental difference is receptor pharmacology:

Tirzepatide's results come from large Phase 3 programs and years of clinical use. Retatrutide's Phase 2 and early Phase 3 numbers are promising but await validation across the full TRIUMPH program.

The glucagon component provides a mechanistic explanation for the efficacy difference. By increasing resting energy expenditure, retatrutide may overcome the metabolic adaptation that limits weight loss durability with appetite-suppressing drugs alone.

Key Takeaways

• Retatrutide is a first-in-class triple agonist (GLP-1/GIP/glucagon) that produced 28.7% weight loss in Phase 3 trials
• The glucagon receptor component increases energy expenditure and promotes liver fat oxidation, which dual agonists like tirzepatide cannot achieve
• Liver fat reduction of up to 86% positions retatrutide as a potential treatment for MASLD/MASH
• Dysesthesia (abnormal skin sensations) is a new safety signal affecting approximately 1 in 5 patients at the highest dose
• FDA approval is projected for late 2027, with commercial availability likely in early 2028
• A head-to-head trial comparing retatrutide and tirzepatide will report results in December 2026

Frequently Asked Questions

Is retatrutide approved by the FDA?

No. Retatrutide is an investigational drug currently in Phase 3 clinical trials. Eli Lilly is expected to submit a New Drug Application in late 2026 or early 2027, with FDA approval projected for late 2027.

How is retatrutide different from semaglutide and tirzepatide?

Semaglutide targets only GLP-1 receptors. Tirzepatide targets GLP-1 and GIP receptors. Retatrutide targets all three plus glucagon receptors, adding energy expenditure effects that the other drugs lack.

What does the glucagon receptor do for weight loss?

Glucagon receptor activation increases thermogenesis (heat production), promotes lipolysis (fat breakdown), stimulates liver fat oxidation, and raises resting energy expenditure. This counteracts the metabolic slowdown that normally accompanies weight loss.

Is retatrutide more effective than tirzepatide?

Early data suggests yes. Retatrutide produced 28.7% weight loss vs. tirzepatide's ~21% in separate trials. A direct head-to-head comparison will report in December 2026 and provide definitive data.

What are the main side effects of retatrutide?

Gastrointestinal symptoms (nausea, diarrhea, constipation, vomiting) are most common. Dysesthesia (tingling or altered skin sensations) is a new signal affecting about 20% of patients at the 12 mg dose.

When will retatrutide be available?

Assuming successful completion of Phase 3 trials and FDA approval, commercial availability is expected in late 2027 or early 2028.

Conclusion

Retatrutide represents a significant advance in obesity pharmacotherapy. By adding glucagon receptor agonism to the established GLP-1/GIP pathway, it achieves weight loss results that approach surgical outcomes without the invasiveness of bariatric procedures.

The Phase 3 TRIUMPH program will determine whether these early results hold up across larger patient populations and longer durations. Safety monitoring of the dysesthesia signal will be particularly important for regulatory review.

For researchers and clinicians tracking the obesity drug pipeline, retatrutide is the most important compound in late-stage development. The December 2026 head-to-head data against tirzepatide will clarify whether triple agonism truly represents the next standard of care.

This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational drug not approved by the FDA. Consult a healthcare provider before considering any peptide therapy.

Sources

• Eli Lilly TRIUMPH-4 Results Announcement
• NEJM: Triple Hormone Receptor Agonist Retatrutide Phase 2 Trial
• Nature: Structural Insights into Retatrutide Triple Agonism
• Nature Medicine: Retatrutide for MASLD Phase 2a Trial
• PMC: Comparative Efficacy of Tirzepatide vs Retatrutide Meta-Analysis
• ClinicalTrials.gov: TRIUMPH-4 Study (NCT05931367)
• PMC: Retatrutide Game Changer in Obesity Pharmacotherapy
• BioSpace: TRIUMPH Trial Results and Safety Signals